Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
HOME > REGULATORY
REGULATORY
- PMDA Draws Up "Global Vision" to Establish World Class Position
November 10, 2011
- MHLW Proposes Raising GE Dispensing Rates to Receive Upper Premiums for GE Dispensing Systems
November 10, 2011
- Mr Kobayashi of Kyokai Kenpo Proposes Measures to Promote GE Drug Use
November 10, 2011
- Applications for “Regulatory Strategy Consultation” Increasing Rapidly: Mr Isobe of PMDA
November 10, 2011
- Promote “Category-based” Negotiations Instead of Package Deals: Mr Hasegawa
November 10, 2011
- PAFSC Committee Approves Extension of Reexamination Period for DSP’s Lonasen
November 9, 2011
- MHLW Announces Add’l Indications Eligible for Applications Based on Info in Public Domain
November 9, 2011
- 1st PAFSC Committee Recommends Approval for Products Including Eisai’s Lunesta
November 8, 2011
- MHLW Announces Additional Indications for 3 APIs Following Prior Assessments
November 7, 2011
- CSIMC Approves Plan to Ban Use of “Dispensing Point” Cards by Pharmacies, Drugstores
November 4, 2011
- CSIMC Subcommittee Approves Proposal to Expand Range of Drugs Subject to Re-pricing
November 4, 2011
- Japan, China, S. Korea Agree to Draft GL on Joint Clinical Trials
November 2, 2011
- Chuikyo Subcommittee Approves Proposal to Expand Range of Drugs Subject to Re-pricing
November 2, 2011
- Chuikyo Approves Plan to Ban Use of “Dispensing Point” Cards by Pharmacies, Drugstores
November 2, 2011
- Committee Recommends Approval of 3 Products Including MSD’s Rota Teq
November 1, 2011
- Business Sector Call for Japan to Join TPP Talks Voiced at National Strategy Council Meeting
November 1, 2011
- Korosho to Ask Doctors to Exercise Caution in Co-prescribing 3 or More Psychotropics
November 1, 2011
- Healthcare Reps at Chuikyo Call For Quality Assurance to Promote GE Use
November 1, 2011
- WT of DPJ Begins Discussion, Not Yet Known If It Covers Drug Pricing System
October 31, 2011
- Medical Benefits Rose 4.2% in FY2009, Breaking ¥30 Tril. for 1st Time
October 31, 2011
ページ
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…